News and reporting on prostate cancer.
The company had total revenues of $193.5 million during the quarter, driven by continued increases in revenue and test volume for its more recently launched and acquired tests.
Test volume and revenues increased in the US, especially in prostate cancer. Meanwhile, international test volume was down but corresponding revenue increased.
In Cell this week: genome sequencing analysis of Egyptian bat, "chemistry-first" approach to find personalized lung cancer treatment targets, and more.
In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.
The firm said total test volumes rose 55 percent during the quarter, and test volumes for its SelectMDx liquid biopsy test nearly tripled in Europe.
In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.
In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.
UK researchers have uncovered about 80 proteins that could be targeted to treat prostate cancer, the Times reports.
At a time of rapid growth in the consumer genetics space, PerkinElmer and NorthShore are developing digital apps to ease access to genetic disease risk information through Helix.
PerkinElmer is working on an app that reports pathogenic or likely pathogenic ACMG-59 genetic variants, and NorthShore's app will report a prostate cancer risk score.
Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.
An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.
Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.
In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.